東寶生物(300239.SZ):一季度淨利潤預增332.09%-461.71%
格隆匯3月23日丨東寶生物(300239.SZ)公佈2022年第一季度業績預吿,公司預計實現2022年第一季度歸屬於上市公司股東的淨利潤為2000萬元–2600萬元,同比增長332.09%-461.71%;預計實現扣除非經常性損益後的淨利潤為1850萬元–2400萬元,同比增長710.55%-951.52%。
業績變動原因系:
1、報吿期內,明膠系列產品業務穩步發展,市場需求向好,銷售收入較上年同期實現進一步增長,盈利能力同比增幅較大,銷售利潤增加。
2、報吿期內,受益於公司“膠原+”系列產品的不斷深入推廣,膠原蛋白系列產品業務穩步發展,銷售收入同比增幅較大,銷售利潤增加。
3、報吿期內,非經常性損益對淨利潤的貢獻金額預計為100萬元-200萬元,較上年同期減少34.63萬元-134.63萬元。非經常性利潤貢獻主要是公司前期收到的政府補貼資金本期攤銷轉入當期損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.